Skip to main content
Clinical Trials/NCT05027191
NCT05027191
Completed
Not Applicable

Evaluating the Effect of Desflurane Versus Sevoflurane With Recent Biomarkers of Renal and Hepatic Function in Laparoscopic Cholecystectomy Patients: A Prospective Randomized Double Blinded Study

Theodor Bilharz Research Institute1 site in 1 country70 target enrollmentFebruary 15, 2018

Overview

Phase
Not Applicable
Intervention
Sevoflurane
Conditions
Postoperative Complications
Sponsor
Theodor Bilharz Research Institute
Enrollment
70
Locations
1
Primary Endpoint
Change in serum Neutrophil gelatinase-associated lipocalin (NGAL)
Status
Completed
Last Updated
4 years ago

Overview

Brief Summary

Studying the effects of both inhalational anesthetics desflurane and sevoflurane on hepatic integrity and renal function, guided by recent blood and urine biomarkers in patients undergoing laparoscopic cholecystectomy surgery.

Registry
clinicaltrials.gov
Start Date
February 15, 2018
End Date
December 1, 2019
Last Updated
4 years ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

khalda Galal Moustafa

Principal Investigator

Theodor Bilharz Research Institute

Eligibility Criteria

Inclusion Criteria

  • American Society of Anesthesiologists (ASA) Class: I\&II.
  • Elective laparoscopic cholecystectomy.
  • Age: 25-55 years.
  • Gender: Both male and female.
  • Body Mass Index (BMI): 18.5-24.9 km2-(Normal weight).

Exclusion Criteria

  • Extremes of age.
  • Abnormal hepatic function by alanine aminotransferase (ALT) and aspartate aminotransferase (AST) values outside the normal range.
  • Abnormal renal function by blood urea nitrogen (BUN) and creatinine above the normal ranges.
  • Hypertension, unstable angina pectoris or myocardial infarction within the last six months.
  • Pregnancy and lactation.
  • Bronchial asthma.
  • Drug allergies.
  • Alcohol or drug addiction.
  • General anesthesia within the last three months.

Arms & Interventions

Sevoflurane

This group will receive sevoflurane as the maintenance inhalational anesthetic.

Intervention: Sevoflurane

Sevoflurane

This group will receive sevoflurane as the maintenance inhalational anesthetic.

Intervention: Neutrophil Gelatinase-Associated Lipocalin (NGAL)

Desflurane

This group will receive desflurane as the maintenance inhalational anesthetic.

Intervention: Neutrophil Gelatinase-Associated Lipocalin (NGAL)

Desflurane

This group will receive desflurane as the maintenance inhalational anesthetic.

Intervention: Desflurane

Outcomes

Primary Outcomes

Change in serum Neutrophil gelatinase-associated lipocalin (NGAL)

Time Frame: a change from baseline NGAL serum level at 6 hours

Renal Biomarker

Secondary Outcomes

  • Change in serum Arginase(Baseline, first hour, six hours, after 24 hours)
  • Change in serum Cystatin-c(Baseline, first hour, six hours, after 24 hours)
  • Change in urine Interleukin-18(Baseline, first hour, six hours, after 24 hours)
  • Change in urine Netrin-1(Baseline, first hour, six hours, after 24 hours)
  • Change in urine Kidney Injury Molecule(Baseline, first hour, six hours, after 24 hours)
  • Change in urine Alpha-Glutathione S-Transferase(Baseline, first hour, six hours, after 24 hours)

Study Sites (1)

Loading locations...

Similar Trials